Research square · 2026

Relative efficacy, safety and immunogenicity of bivalent versus monovalent COVID-19 mRNA booster vaccines: a randomized trial.

СтатьяПрепринтНазвание и аннотация: Перевод в очереди

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Dadabhai Sufia, Samandari Taraz, Zhang Bo, Hudson Aaron, Mkhize Nonhlanhla N, Tapley Asa, Andriesen Jessica, Moore Penny L, Chirenje Zvavahera, Elyanu Peter James, Makhema Joseph, Kamuti Ethel, Nuwagaba-Biribonwoha Harriet, Kee Jia Jin, Hu Jiani, Baloyi-Oseh Katekani, Shah Parth, Khuto Kentse, Miner Maurine D, Lessells Richard, Bhebhe Sinethemba, Hermanus Tandile, Kaldine Haajira, Takalani Azwidihwi, Yacovone Margaret, Polakowski Laura, Hural John, Fisher Leigh H, Margaret Craig A, Aweyo Florence, Badal-Faesen Sharlaa, Brumskine William L, Coetzer Soritha, Dawson Rodney, Delany-Moretlwe Sinead, Gill Katherine M, Hosseinipour Mina C, Innes Steve, Kassim Priya, Kafulafula Emmanuel George, Laher Fatima, Mandona Nelly M, Malahleha Moelo, Malulike Vongane L, Mathebula Matsontso, Mboya Grace, Mitha Essack, Mngadi Kathryn, Mda Pamela, Moloantoa Tumelo, Naicker Nivashnee, Naicker Vimla, Nanvubya Annet, Nchabeleng Maphoshane, Otieno Walter, Potgieter Elsje L, Potloane Disebo, Punt Zelda, Said Jamil A, Singh Yashna, Tayob Mohammed S, Wabwire Deo O, Cohen Myron S, McElrath M Juliana, Andersen-Nissen Erica, Ferrari Guido, Kublin James G, Bekker Linda-Gail, Gilbert Peter B, Mgodi Nyaradzo M, Kotze Philip L, Huang Yunda, Garrett Nigel, Gray Glenda E, Corey Lawrence

Аннотация

The relative efficacy, safety, and immunogenicity of monovalent mRNA-1273 (ancestral WA1) versus bivalent mRNA-1273.222 (ancestral plus omicron BA.4/BA.5) boosting have not been studied prospectively where HIV and SARS-CoV-2 seroprevalence are high. CoVPN 3008 (NCT05168813) was a randomized, double-blinded trial in seven African countries during omicron waves, enrolling people with HIV (PWH) or comorbidities associated with severe COVID-19 who had previously received mRNA-1273. Participants were randomized 1:1 to intramuscular monovalent or bivalent booster and routinely PCR-tested for SARS-CoV-2. Between 10/2022 and 03/2023, 3,988 participants (3,086 PWH) received bivalent (n=2012) or monovalent (n=1976) booster. By month 12, 293 COVID-19 cases and 221 asymptomatic infections occurred, including one severe case. COVID-19 rates did not differ between arms (hazard ratio [HR] 0.92, 95% CI 0.73-1.15, P=0.45). Combined COVID-19 and asymptomatic infection was 15% lower with the bivalent (239 vs. 275; HR 0.85, 0.71-1.01, P=0.07), and asymptomatic infection alone was 24% lower (HR 0.76, 0.59-1.00, P=0.05). Neutralizing antibody titers to BA.4/5 and XBB.1.5, measured in 100 PWH per arm, boosted higher in bivalent recipients (P=0.026 and 0.002). Adverse events were similar. In predominantly PWH, the bivalent booster was well tolerated, elicited superior immunogenicity against omicron variants, and appeared to protect against asymptomatic infection but not COVID-19.

Relative efficacy, safety and immunogenicity of bivalent versus monovalent COVID-19 mRNA booster vaccines: a randomized trial.

Ошибки и ограничения

Аннотация